1,376 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
NVS Novartis AG $85.13 $197.65B N/A
Article Searches
Biogen Up on New Data on Alzheimer's Candidate Aducanumab http://www.zacks.com/stock/news/657638/biogen-up-on-new-data-on-alzheimers-candidate-aducanumab?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-657638 Dec 06, 2019 - Biogen (BIIB) divulges new positive data on Alzheimer's candidate, aducanumab at CTAD. Stock rises.
Regeneron Reports Positive Data on Rare Blood Disorder Drug http://www.zacks.com/stock/news/657613/regeneron-reports-positive-data-on-rare-blood-disorder-drug?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-657613 Dec 06, 2019 - Regeneron (REGN) announces positive top-line data from a phase II study on rare blood disorder drug.
Why Novartis's $9.7 Billion Purchase of The Medicines Company Is Bad News for Amgen https://www.fool.com/investing/2019/12/02/why-novartis-97-billion-purchase-of-the-medicines.aspx?source=iedfolrf0000001 Dec 02, 2019 - Novartis's purchase comes with investigational cardiovascular drug inclisiran, a competitor with potential to dethrone Amgen's already embattled Repatha.
5 New Drug Approvals the FDA Gave Top Priority https://www.fool.com/investing/2019/11/29/5-new-drug-approvals-the-fda-gave-top-priority.aspx?source=iedfolrf0000001 Nov 29, 2019 - Here's why the FDA recently approved five new drugs way ahead of schedule.
Euronav NV Frontline IMO 2020 Strategies: Assessing Which Will Be Superior https://seekingalpha.com/article/4309663-euronav-nv-frontline-imo-2020-strategies-assessing-will-superior?source=feed_all_articles Nov 28, 2019 - IMO 2020 sulfur regulation goes into effect January 1, 2020.Frontline has chosen a scrubber strategy.Euronav has chosen a pre-purchase at bulk prices and store compliant fuel.The most economical strat
Global Blood's (GBT) Oxbryta Secures FDA Approval for SCD http://www.zacks.com/stock/news/642646/global-bloods-gbt-oxbryta-secures-fda-approval-for-scd?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-642646 Nov 27, 2019 - Global Blood's (GBT) Oxbryta wins the FDA nod to address sickle cell disease in patients aged 12 years and above. The approval comes three months ahead of schedule.
CRISPR vs. Gene Therapy Round 1: What Investors Need to Know https://www.fool.com/investing/2019/11/26/crispr-vs-gene-therapy-round-1-what-investors-need.aspx?source=iedfolrf0000001 Nov 26, 2019 - There’s still a long way to go, but the newcomer is off to a good start.
4 Big Drug Stocks Ripe for Takeover After NVS-MDCO Deal http://www.zacks.com/stock/news/638202/4-big-drug-stocks-ripe-for-takeover-after-nvs-mdco-deal?cid=CS-ZC-FT-analyst_blog|industry_focus-638202 Nov 26, 2019 - Here are four stocks that boast promising prospects and are most likely to be takeout targets.
Roche's NDA for SMA Drug Risdiplam Gets Priority Review http://www.zacks.com/stock/news/637403/roches-nda-for-sma-drug-risdiplam-gets-priority-review?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-637403 Nov 25, 2019 - The FDA accepts Roche's (RHHBY) NDA for risdiplam under a priority review to treat spinal muscular atrophy. A verdict is pending on May 24, 2020.
Novartis (NVS) to Acquire The Medicines Company for $9.7B http://www.zacks.com/stock/news/636880/novartis-nvs-to-acquire-the-medicines-company-for-%2497b?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-636880 Nov 25, 2019 - Novartis (NVS) set to acquire The Medicines Company and add a promising candidate to its cardiovascular pipeline.

Pages: 123456...138

Page 1>